Sign In
Buy PLRX
$1.18
+0.0200 (+1.72%)
At Close: Jun 03, 2026
Pliant Therapeutics to Participate in Upcoming Investor Events
08:00am, Wednesday, 01'st May 2024
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel ther
Pliant Therapeutics to Participate in Upcoming Investor Events
08:00am, Tuesday, 02'nd Apr 2024
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel th
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
10:23am, Wednesday, 27'th Mar 2024
Bexotegrast clinical poster selected for featured oral presentation at ATS 2024 Mini Symposium SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX),
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
07:30am, Tuesday, 12'th Mar 2024
Acceptance by European Union and other global health authorities of the pivotal, adaptive Phase 2b/3 trial will significantly shorten bexotegrast's time to Phase 3 data
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
11:01am, Thursday, 07'th Mar 2024
Pliant Therapeutics, Inc. (PLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
04:03pm, Tuesday, 27'th Feb 2024
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN FRA
Pliant Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Monday, 26'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the
Pliant Therapeutics to Participate in Upcoming Investor Events
08:00am, Wednesday, 07'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 03'rd Jan 2024
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is sche
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
04:05pm, Thursday, 09'th Nov 2023
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review recommends INTEGRIS-PSC trial continue without modification
Is a Surprise Coming for Pliant Therapeutics (PLRX) This Earnings Season?
09:47am, Thursday, 09'th Nov 2023
Pliant Therapeutics (PLRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Pliant Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 08'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel the
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:16am, Tuesday, 07'th Nov 2023
Pliant Therapeutics, Inc. (PLRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
